Piramal Pharma Ltd
PPLPHARMAPiramal Pharma Ltd
PPLPHARMA![](https://assets.tickertape.in/sector-icons/health_care.png)
![](https://assets.tickertape.in/sector-icons/smallcap.png)
![](https://assets.tickertape.in/sector-icons/moderate_risk.png)
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
867.50 | 3.04 | 0.06% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
49.93 | 6.39 | 0.52% |
Forecast & Ratings
Detailed Forecast from 6 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Piramal Pharma Ltd is a manufacturer of pharmaceutical preparation. It offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 14 global facilities and a global distribution network in over 100 countries. The Company is located in Mumbai, India.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Zydus Lifesciences Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | |||||
---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 6,544.48 | 6,893.93 | 7,360.99 | 8,406.04 | 8,597.57 | |||||
Raw Materials | 2,111.85 | 2,396.03 | 2,634.66 | 3,152.60 | 7,167.81 | |||||
Power & Fuel Cost | 136.70 | 163.56 | 207.81 | 241.59 | ||||||
Employee Cost | 1,467.74 | 1,588.83 | 1,896.35 | 2,029.50 | ||||||
Selling & Administrative Expenses | 709.63 | 868.15 | 917.47 | 994.33 | ||||||
Operating & Other expenses | 461.02 | 607.95 | 803.98 | 619.67 | ||||||
EBITDA | 1,657.54 | 1,269.41 | 900.72 | 1,368.35 | 1,429.76 | |||||
Depreciation/Amortization | 545.04 | 586.18 | 676.69 | 740.57 | 751.51 | |||||
PBIT | 1,112.50 | 683.23 | 224.03 | 627.78 | 678.25 | |||||
Interest & Other Items | 163.45 | 198.25 | 344.18 | 448.49 | 436.93 | |||||
PBT | 949.05 | 484.98 | -120.15 | 179.29 | 241.32 | |||||
Taxes & Other Items | 114.02 | 109.02 | 66.31 | 161.47 | 213.56 | |||||
Net Income | 835.03 | 375.96 | -186.46 | 17.82 | 27.76 | |||||
EPS | 8.20 | 3.37 | -1.53 | 0.14 | 0.21 | |||||
DPS | 0.00 | 0.55 | 0.00 | 0.11 | 0.00 | |||||
Payout ratio | 0.00 | 0.16 | 0.00 | 0.79 | 0.00 |
Company Updates
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Piramal Pharma Ltd | 1,351.40 | 3.04 | 0.06% |
Sun Pharmaceutical Industries Ltd | 45.08 | 6.43 | 0.75% |
Cipla Ltd | 31.71 | 4.88 | 0.80% |
Torrent Pharmaceuticals Ltd | 70.18 | 16.95 | 0.82% |
Price Comparison
Compare PPLPHARMA with any stock or ETFShareholdings
Promoter Holdings Trend
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Shareholding History
Mutual Funds Holding Trend
Increased Mutual Fund Holding
In last 3 months, mutual fund holding of the company has increased by 1.11%
Top 5 Mutual Funds holding Piramal Pharma Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
HDFC Flexi Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 4.9696% | Percentage of the fund’s portfolio invested in the stock 2.02% | Change in the portfolio weight of the stock over the last 3 months 0.62% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 14/57 (+7) |
HDFC Focused 30 Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.5352% | Percentage of the fund’s portfolio invested in the stock 2.68% | Change in the portfolio weight of the stock over the last 3 months 0.41% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 11/36 (+8) |
Franklin India Opportunities Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.4112% | Percentage of the fund’s portfolio invested in the stock 1.97% | Change in the portfolio weight of the stock over the last 3 months -0.10% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 39/66 (-3) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJul 12, 2024
Dividend/Share
₹0.11
Ex DateEx Date
Jul 12, 2024
Piramal Pharma Q1FY25 results: Net loss narrows at Rs 88.64 crore
![](https://pocket-image-cache.com/direct?url=http://bsmedia.business-standard.com/_media/bs/img/article/2024-07/19/thumb/fitandfill/400X400/1721399234-6789.jpg)
Net Loss of Piramal Pharma reported to Rs 88.64 crore in the quarter ended June 2024 as against net loss of Rs 98.58 crore during the previous quarter ended June 2023. Sales rose 11.57% to Rs 1951.14 crore in the quarter ended June 2024 as against Rs 1748.85 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales1951.141748.85 12 OPM %10.487.57 - PBDT139.4766.50 110 PBT-45.08-107.11 58 NP-88.64-98.58 10 Powered by Capital Market - Live
Revenue from operations grew by 11.57% year on year (YoY) to Rs 1,951.14 crore during the quarter, driven by robust high-teen growth in the CDMO business and steady double-digit growth in the ICH business. The company's revenue from contract development and manufacturing organization (CDMO) was at Rs 1,057 crore (up 18% YoY), complex hospital generics (CHG) stood at Rs 631 crore (up 2% YoY) and India consumer healthcare (ICH) came in at Rs 264 crore (up 10% YoY) during the period under review. The drug maker posted a pre-tax loss of Rs 45.08 crore in Q1 FY25 as compared with pre-tax loss of Rs 107.11 crore recorded in same quarter last year. EBITDA grew 31% YoY to Rs 224 crore with EBITDA margin of 11%, a YoY improvement of over 170bps, driven by operating leverage, cost optimization measures and superior revenue mix. Nandini Piramal, chairperson of Piramal Pharma, said, 'We delivered a healthy revenue growth accompanied by over 170bps YoY expansion in EBIDTA margin driven by favorable revenue mix and cost optimization initiatives. Our CDMO business continues to witness sustained order inflows, especially for on-patent commercial manufacturing. We are also seeing good demand for our differentiated offerings with increase in customer enquiries and visits. In our CHG business, our planned expansion for inhalation anesthesia portfolio is on track and is expected to get commercialized in FY26. Our India Consumer Healthcare business is also delivering steady growth driven by power brands and strong traction in e-commerce channel. As a responsible organisation, we are taking good strides in our journey towards building sustainable operations. Our continuous efforts in quality and compliance bore fruits with successful closure of USFDA inspections at two of our facilities at Lexington (USA) and PPDS (Analytical Services, India). Historically our H2 outperforms H1, both in terms of revenue and profitability, and we expect this trend to continue in FY25. We intend to further build on to the good start that we have had to the financial year.' Piramal Pharma (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business; and the India Consumer Healthcare business, selling over-the-counter products. The scrip declined 0.66% to Rs 165.15 on the BSE.Powered by Capital Market - Live
Piramal Pharma has granted 48,30,836 stock options under Employee Stock Option and Incentive Plan on 26 July 2024. Powered by Capital Market - Live
Piramal Pharma will hold a meeting of the Board of Directors of the Company on 26 July 2024.Powered by Capital Market - Live
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant